Agreement provides patients with broader access to a protein-based non-mRNA adjuvanted COVID-19 vaccine through combined commercial strength, fro...
ArkeaBio™, a leading ag-biotech start-up developing a vaccine to reduce livestock methane emissions, announced the close of a $26.5 million Series A ...
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that Merck for Mothers, the company’s global materna...
QIAGEN announced a cooperative research and development agreement (CRADA) with the U.S. Federal Bureau of Investigation (FBI) to develop a novel test for i...
- CX-801 is a dually masked, conditionally activated IFNα2b cytokine designed using the CytomX Probody® Therapeutic Platform - - Phase 1 first-i...
BrightInsight, Inc, the trusted partner and platform driving value for top biopharma compliant digital health solutions, announced today that it will deplo...
Walgreens and Boehringer Ingelheim announced a strategic collaboration aimed at optimizing recruitment and making clinical trials more accessible, inclusiv...
Thermo Fisher Scientific, the world leader in serving science, was proud to welcome Jozef Sikela, Minister of Industry and Trade of the Czech Republic, alo...
BrioHealth Solutions, Inc., a medical technology company focused on developing innovative advanced heart failure solutions, announced it has received FDA I...
The Company expects to initiate a Phase 1 clinical trial in PD in 2H 2024. NKGen Biotech, Inc. , a clinical-stage biotechnology company focused on the dev...
Celltrion USA announced that it has signed an agreement with Express Scripts, one of the nation's leading pharmacy benefit managers (PBMs) negotiating on b...
Multiply Labs, a robotics company developing industry-leading automated manufacturing systems to produce individualized drugs, and GenScript Biotech Corpor...
Transaction provides company with an estimated approximately $128 million in cost savings, including approximately $67 million in clinical de...
Rilzabrutinib LUNA 3 phase 3 study met primary endpoint in immune thrombocytopenia Pivotal data from the first phase 3 study of a BTKi in immune thrombo...
© 2024 Biopharma Boardroom. All Rights Reserved.
